# Running a pre-launch compliance check before a campaign goes live
A single unapproved word on a banner ad once cost a major pharmaceutical company a public FDA warning letter, a pulled campaign, and weeks of remediation, all because a claim of "improved outcomes" appeared without the required qualifying data. That is the reality of MLR (Medical, Legal, Regulatory) review: it is not paperwork theater, it is the last line of defense before a claim reaches a patient or a physician.
This lesson walks through what actually happens in the days before a pharma campaign asset goes live, so you can anticipate objections before they cost you a launch date.
MLR stands for Medical, Legal, Regulatory: the three-function committee that most pharmaceutical and biotech companies convene to approve every promotional asset before publication. It typically includes:
In the US, the relevant FDA body is the Office of Prescription Drug Promotion (OPDP), part of the FDA's Center for Drug Evaluation and Research. OPDP can issue Untitled Letters (minor violations) or Warning Letters (serious violations, often demanding immediate campaign withdrawal). See the FDA's own
In Europe, there is no single EMA-run advertising police force. Advertising to consumers for prescription drugs is banned outright under EU law (Directive 2001/83/EC), and advertising to healthcare professionals is regulated at the national level, often through industry self-regulatory bodies like the UK's PMCPA (Prescription Medicines Code of Practice Authority), which enforces the ABPI Code.
Three regulatory pillars show up in nearly every MLR checklist:
1. Fair balance. Any claim of efficacy must be accompanied by comparably prominent risk information. A TV ad claiming a drug "controls symptoms" cannot bury the side-effect list in tiny disclaimer text at the bottom.
2. Substantiation. Every claim needs a citable source, usually the approved product label or a peer-reviewed trial. "Fewer flare-ups" needs a number and a study, not a feeling.
3. Off-label promotion ban. Marketing cannot promote uses, populations, or dosing not included in the drug's approved label. This is one of the most heavily enforced areas: several billion-dollar settlements in the US pharmaceutical industry have stemmed from off-label promotion allegations (for example, historical cases involving Pfizer and GlaxoSmithKline, both publicly documented in Department of Justice settlements).
Imagine a digital banner ad for a Type 2 diabetes drug, running only in the US, aimed at healthcare professionals (HCPs) on a clinical portal.
Step 1: Claim-by-claim mapping.
Every factual statement gets tagged to its source. "Reduces HbA1c by an average of 1.2%" must trace to a specific clinical trial table, with the citation logged in the review software (most large pharma companies use platforms like Veeva Vault PromoMats for this).
Step 2: Indication check.
Confirm the ad only discusses the approved indication. If the drug is approved for adults with Type 2 diabetes, an image implying use in adolescents is a red flag, even if unintentional.
Step 3: Fair balance layout check.
Legal checks the visual hierarchy: is the risk information (black box warnings, common side effects) at least as visible as the benefit claim? A common objection: benefit claims in bold 24-point font, risk information in 8-point gray text. That imbalance alone can trigger an Untitled Letter.
Step 4: Comparator claims.
If the ad says "more effective than [Competitor Drug]," medical must confirm this is from a head-to-head trial, not two separate trials compared informally. Indirect comparisons without direct trial data are a frequent MLR rejection reason.
Step 5: Channel-specific rules.
Social media snippets have character limits that make fair balance hard to fit. FDA guidance (non-binding but influential) suggests that if you cannot fit adequate risk information in the post itself, you need a direct, unbroken link to it. This is why you often see pharma tweets or LinkedIn posts that look oddly sparse, then link out immediately.
Step 6: Reference and legal archive.
Legal confirms the piece is archived per SOP retention rules (in the US, typically for the life of the promotional campaign plus a required retention window, often several years, per company policy and FDA recordkeeping expectations).
Based on publicly available OPDP letters, the most frequent objection categories are consistent year over year:
A useful pattern for marketers: if a claim feels like the *strongest* possible version of the truth, it is often the version MLR will flag first. The safest claims are the most literal restatements of trial data.
Before an asset even reaches formal MLR queue, marketers can self-screen with four questions:
1. Can I point to the exact page and table in the approved label or trial publication for every claim?
2. Is my risk information visually equal in prominence to my benefit claim?
3. Would this claim survive being read aloud next to the FDA-approved label, with no additional context?
4. If this ran in a country with stricter DTC (direct-to-consumer advertising) rules, like anywhere in the EU, would it even be legal to run at all?
That fourth question matters more each year as global campaigns get built once and localized. The US allows DTC prescription drug advertising (one of only two countries in the world to do so, alongside New Zealand); the EU does not. A campaign asset built for a US audience often cannot simply be translated for European HCP or patient channels; it needs a parallel compliance pass.
Vérification des acquis
1. Why is MLR review described as 'the last line of defense' rather than a bureaucratic formality?
2. A pharma marketing claim states a drug shows 'improved outcomes' without citing supporting clinical data. Which MLR function would most likely flag this first, and why?
3. What is a key structural difference between US and European regulation of prescription drug advertising, based on the lesson?
4. Select ALL correct answers about the roles within an MLR review committee.
Sélectionnez toutes les réponses correctes.
5. Select ALL correct answers about the consequences and purpose of FDA OPDP enforcement actions.
Sélectionnez toutes les réponses correctes.
Smart marketing teams do not treat MLR as a gate at the end; they treat it as a filter built into creative development. Practical habits:
🎬 [VIDEO: "FDA Regulation of Prescription Drug Advertising" - youtube.com - search for FDA OPDP or industry compliance channel explainers on how drug ad claims are reviewed and enforced, useful for seeing real Warning Letter examples discussed]